Functional characterization of two human receptor activity-modifying protein 3 variants

Peptides

Volumn 31, Issue 4, 2010, Pages 579-584

  Bailey, Richard J ^a   Bradley, Joshua W I ^a   Poyner, David R ^b   Rathbone, Dan L ^b   Hay, Debbie L ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

Adrenomedullin; Amylin; RAMP3; Receptor activity modifying protein

Indexed keywords

AMINO ACID; AMYLIN; ARGININE; CYSTEINE; LEUCINE; PHENYLALANINE; PROLINE; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; RECEPTOR PROTEIN; SERINE; TRYPTOPHAN;

ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CELL SURFACE; CONTROLLED STUDY; GENE MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN CONFORMATION; PROTEIN ISOFORMS; RECEPTORS, G-PROTEIN-COUPLED;

HOMO SAPIENS;

EID: 77649235207     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.12.016     Document Type: Article

References (31)

1. Bailey R.J., and Hay D.L. Agonist-dependent consequences of proline to alanine substitution in the transmembrane helices of the calcitonin receptor. Br J Pharmacol 151 (2007) 678-687
2. Bailey R.J., and Hay D.L. Pharmacology of the human CGRP1 receptor in Cos 7 cells. Peptides 27 (2006) 1367-1375
3. Bomberger J.M., Parameswaran N., Hall C.S., Aiyar N., and Spielman W.S. Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. J Biol Chem 280 (2005) 9297-9307
4. Bouschet T., Martin S., and Henley J.M. Receptor-activity-modifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane. J Cell Sci 118 (2005) 4709-4720
5. Case D.A.C.T., Darden T., Gohlke H., Luo R., Merz K.M., Onufriev A., et al. The Amber biomolecular simulation programs. J Comput Chem 26 (2005) 1668-1688
6. Christopoulos A., Christopoulos G., Morfis M., Udawela M., Laburthe M., Couvineau A., et al. Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 278 (2003) 3293-3297
7. Cooray S.N., Chan L., Webb T.R., Metherell L., and Clark A.J.L. Accessory proteins are vital for the functional expression of certain G protein-coupled receptors. Mol Cell Endocrinol 300 (2009) 17-24
8. Dackor R., Fritz-Six K., Smithies O., and Caron K. Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age. J Biol Chem 282 (2007) 18094-18099
9. EllisClare. The state of GPCR research in 2004. Nat Rev Drug Discov 3 (2004) 577-626
10. Flahaut M., Pfister C., Rossier B.C., and Firsov D. N-glycosylation and conserved cysteine residues in RAMP3 play a critical role for the functional expression of CRLR/RAMP3 adrenomedullin receptor. Biochemistry 42 (2003) 10333-10341
11. Fritz-Six K.L., Li M., and Caron K.M. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 118 (2008) 40-50
12. Hay D.L., Poyner D.R., and Sexton P.M. GPCR modulation by RAMPs. Pharmacol Ther 109 (2006) 173-197
13. Humphrey W., and Schulten K. VMD-visual molecular dynamics. J Mol Graph 14 (1996) 33-38
14. Ichikawa-Shindo Y.S.T., Kamiyoshi A., Kawate H., Iinuma N., Yoshizawa T., Koyama T., et al. The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest 118 (2008) 29-39
15. Jorgensen W.L., Madura J.D., Impey R.W., and Klein M.L. Comparison of simple potential functions for simulating liquid water. J Chem Phys 79 (1983) 926-935
16. Kusano S., Kukimoto-Niino M., Akasaka R., Toyama M., Terada T., Shirouzu M., et al. Crystal structure of the human receptor activity-modifying protein 1 extracellular domain. Protein Sci 17 (2008) 1907-1914
17. Kuwasako K., Kitamura K., Nagata S., and Kato J. Functions of the extracellular histidine residues of receptor activity-modifying proteins vary within adrenomedullin receptors. Biochem Biophys Res Commun 377 (2008) 109-113
18. Kuwasako K.K.K., Uemura T., Nagoshi Y., Kato J., and Eto T. The function of extracellular cysteines in the human adrenomedullin receptor. Hypertens Res 26 (2003) S25-31
19. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 (1998) 333-339
20. Metherell L.A., Chapple J.P., Cooray S., David A., Becker C., Ruschendorf F., et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat Genet 37 (2005) 166-170
21. Morfis M., Tilakaratne N., Furness S.G.B., Christopoulos G., Werry T.D., Christopoulos A., et al. Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology 149 (2008) 5423-5431
22. Okumura H., Nagaya N., Itoh T., Okano I., Hino J., Mori K., et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 109 (2004) 242-248
23. Ryan G.J., Jobe L.J., and Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 27 (2005) 1500-1512
24. Schoneberg T., Schulz A., Biebermann H., Hermsdorf T., Rompler H., and Sangkuhl K. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther 104 (2004) 173-206
25. Simms J., Hay D.L., Bailey R.J., Konycheva G., Bailey G., Wheatley M., et al. Structure function analysis of RAMP1 by alanine mutagenesis. Biochemistry 48 (2009) 198-205
26. Simms J., Hay D.L., Wheatley M., and Poyner D.R. Characterization of the structure of RAMP1 by mutagenesis and molecular modeling. Biophys J 91 (2006) 662-669
27. Suzuki Y., Yoshitomo-Nakagawa K., Maruyama K., Suyama A., and Sugano S. Construction and characterization of a full length-enriched and a 5′-end-enriched cDNA library. Gene 200 (1997) 149-156
28. Tao Y.-X. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacol Ther 111 (2006) 949-973
29. Udawela M., Christopoulos G., Morfis M., Christopoulos A., Ye S., Tilakaratne N., et al. A critical role for the short intracellular C terminus in receptor activity-modifying protein function. Mol Pharmacol 70 (2006) 1750-1760
30. Wang J.C.P., and Kollman P.A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?. J Comput Chem 21 (2000) 1049-1074
31. Weinstein L.S., Chen M., Xie T., and Liu J. Genetic diseases associated with heterotrimeric G proteins. Trends Pharmacol Sci 27 (2006) 260-266